Subacute Cutaneous Lupus Erythematosus
Immunology·MeSH: Lupus Erythematosus, Cutaneous
Prevalence
5.0 / 100K
2 drugs in development·1 company·3 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| biib059 | BIOGEN INC. (BIIB) |
Phase 1(1)
| Drug | Company |
|---|---|
| Litifilimab | BIOGEN INC. (BIIB) |
Compare drugs
Frequently asked questions
How many drugs are in development for Subacute Cutaneous Lupus Erythematosus?
BioSniper tracks 2 drugs in development for Subacute Cutaneous Lupus Erythematosus across 1 company.
How many clinical trials target Subacute Cutaneous Lupus Erythematosus?
There are 3 clinical trials targeting Subacute Cutaneous Lupus Erythematosus tracked by BioSniper.
What is the prevalence of Subacute Cutaneous Lupus Erythematosus?
The estimated prevalence of Subacute Cutaneous Lupus Erythematosus is approximately 5.0 per 100,000 population.
Deep-dive into Subacute Cutaneous Lupus Erythematosus
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis